Autumn Glory Partners’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.79M Buy
+99,888
New +$4.29M 1.36% 16
2026
Q1
Sell
-53,634
Closed -$2.73M 220
2025
Q4
$2.73M Buy
53,634
+5,552
+12% +$284K 0.96% 23
2025
Q3
$2.67M Buy
48,082
+8,228
+21% +$482K 1.1% 24
2025
Q2
$2.75M Buy
39,854
+3,724
+10% +$253K 1.29% 19
2025
Q1
$2.37M Buy
36,130
+19,922
+123% +$1.65M 1.17% 21
2024
Q4
$1.39M Sell
16,208
-6,463
-29% -$699K 0.68% 42
2024
Q3
$2.7M Buy
22,671
+6,463
+40% +$862K 1.04% 25
2024
Q2
$2.31M Hold
16,208
1.18% 23
2024
Q1
$2.08M Sell
16,208
-3,000
-16% -$357K 1.02% 29
2023
Q4
$1.99M Sell
19,208
-820
-4% -$81.1K 1.13% 26
2023
Q3
$1.82M Buy
20,028
+4,040
+25% +$356K 1.11% 29
2023
Q2
$1.29M Buy
+15,988
New +$1.31M 0.95% 36
2023
Q1
Sell
-21,788
Closed -$1.47M 167
2022
Q4
$1.47M Sell
21,788
-434
-2% -$25.4K 0.79% 37
2022
Q3
$1.11M Buy
22,222
+17,376
+359% +$931K 0.75% 45
2022
Q2
$270K Sell
4,846
-23,464
-83% -$1.3M 0.2% 108
2022
Q1
$1.57M Sell
28,310
-22,190
-44% -$1.14M 0.91% 33
2021
Q4
$2.83M Buy
+50,500
New +$2.74M 1.18% 23

Other funds holding NVO

Autumn Glory Partners's NVO Position: Q2 2026 in Review

Autumn Glory Partners opened a new position in Novo Nordisk (NVO) in Q2 2026: 99,888 shares worth $4.79M. The stake represents 1.36% of the portfolio and ranks #16 among its holdings. This is a return to the name: Autumn Glory Partners previously reported a position in NVO as recently as Q4 2025.

Autumn Glory Partners first reported a position in NVO in Q4 2021 and has held it in 17 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Autumn Glory Partners held 99,888 shares of Novo Nordisk worth $4.79M as of Q2 2026.
  • Novo Nordisk was a new Autumn Glory Partners position in Q2 2026.
  • Novo Nordisk made up 1.36% of Autumn Glory Partners's portfolio in Q2 2026, its #16 holding.
  • Autumn Glory Partners first reported a position in Novo Nordisk in Q4 2021 and has held it in 17 quarters since.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Autumn Glory Partners's 13F filing for Q2 2026, filed 3 Aug 2026.